Clinical lung cancer最新文献

{"title":"Is Lobectomy Associated With Improved Outcomes Compared to Segmentectomy in Small Cell Lung Cancer Discovered at the Time of Resection?","authors":"Sneha S Alaparthi, Anurag Ishwar, Gregory Whitehorn, Isheeta Madeka, Tyler Grenda, John D Jacob, Nathaniel R Evans Iii, Olugbenga T Okusanya","doi":"10.1016/j.cllc.2025.08.017","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.017","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) represents approximately 10%-15% of all lung cancer cases in the United States. The extent of surgery for early-stage SCLC remains controversial,with the treatment standard being chemotherapy or chemoradiotherapy. We aim to evaluate outcomes among the patients who underwent a lobectomy or segmentectomy in SCLC diagnosed on the day of resection.</p><p><strong>Methods: </strong>This retrospective cohort study utilized the NCDB. We examined patients >18 who underwent a lobectomy or segmentectomy between 2010 and 2019 who had clinically node negative SCLC diagnosed at the time of resection. Outcome variables include 5- year, 30-day, 90-day mortality and readmission rates. Propensity score matching was utilized to compare outcomes between groups.</p><p><strong>Results: </strong>564 patients were examined, with a mean age of 68. Males comprised of 42.9% of the cohort. 65 (12%) patients underwent segmentectomy and 499 (88%) patients underwent lobectomy. There were no differences in nodal upstaging (P = .31) and T stage upstaging (P = .37) between the 2 cohorts. 90.2% of the population was clinical stage I (P = .003). There were no significant differences in 5- year, 30-day, 90-day mortality (P = .22, P = .40, P = .77), and readmission (P = .57) in this cohort. After PSM (n = 118) there continued to be no significant difference in all outcomes between cohorts.</p><p><strong>Conclusions: </strong>In this study, we found that rates of T and N upstaging, 5-year mortality, and short-term outcomes did not differ amongst cohorts, showing that patients who undergo segmentectomy may not benefit from undergoing a more extensive resection.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.","authors":"Haodi Zhou, Beiyu Liang, Li-Chin Lu, Chia-Pang Chan, Jun-He Yang, Shao-Huan Lan","doi":"10.1016/j.cllc.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.008","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) are used in epidermal growth factor receptor (EGFR)-mutant nonsmall-cell lung cancer (NSCLC) after resistance to targeted therapy; however, responses remain limited. This study identified predictors of ICI efficacy to inform treatment strategies.</p><p><strong>Methods: </strong>PubMed, EMBASE, and Web of Science were systematically searched through September 17, 2024, for studies examining associations between clinical benefit and patient characteristics during ICI therapy. Progression-free survival and overall survival were used to determine outcomes.</p><p><strong>Results: </strong>We included 18 studies involving 1151 patients. Combination therapy improved outcomes: ICI plus antiangiogenic therapy versus ICI monotherapy (hazard ratio [HR] = 0.74, 95% confidence interval [CI]: 0.36-1.52) and ICI plus chemotherapy versus ICI monotherapy (HR = 0.45, 95% CI: 0.32-0.65). Predictive genetic factors included atypical versus classical EGFR mutations (HR = 0.45, 95% CI: 0.32-0.64) and exon 21 L858R versus exon 19 deletions (HR = 0.53, 95% CI: 0.40-0.71). Favorable biomarkers included low neutrophil-to-lymphocyte ratio (NLR; HR = 1.90, 95% CI: 1.16-3.11) and positive programmed death ligand-1 (PD-L1) expression (HR = 0.58, 95% CI: 0.35-0.96). Poor Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) was associated with poor outcomes (HR = 2.03, 95% CI: 1.37-3.01). Age, sex, smoking status, and histological subtype exhibited weaker or nonsignificant associations.</p><p><strong>Conclusion: </strong>Patients with atypical EGFR or L858R mutations, high PD-L1 expression, low NLR, and good ECOG-PS are more likely to benefit from ICI therapy. Combining ICIs with chemotherapy or antiangiogenic agents enhances efficacy. Younger age, smoking history, and squamous cell carcinoma may also associate with improved outcomes, but further validation is required.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non-Small Cell Lung Cancer.","authors":"Aakash Desai, Ellen McNeeley, Sanad Alhushki, Mia Haught, Juan Xavier Masjoan Juncos, Dhartiben Patel, Jeffery Brand, Leigh McManus, Sejong Bae, Maya Khalil, Yanis Boumber","doi":"10.1016/j.cllc.2025.08.013","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.013","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have improved outcomes in metastatic non-small cell lung cancer (NSCLC), but benefit in tumors lacking PD-L1 expression remains limited. Dual checkpoint blockade may enhance antitumor immunity by overcoming an immunologically \"cold\" tumor microenvironment. Circulating tumor DNA (ctDNA) is an emerging early response biomarker.</p><p><strong>Patients and methods: </strong>The DISCERN study (UAB 2432) is a single-center, randomized, open-label pilot trial comparing dual immune checkpoint blockade (nivolumab + ipilimumab) plus chemotherapy (Arm A) versus single ICI (pembrolizumab) plus chemotherapy (Arm B) in patients with PD-L1-negative, stage IV NSCLC. The study plans to enroll 24 patients. ctDNA positivity is required at baseline. ctDNA response is evaluated at Cycle 3 Day 1 using Guardant Infinity NGS platform. Primary endpoint is ctDNA molecular response. Secondary endpoints include RECIST-based response rates, progression-free survival (PFS), and overall survival (OS).</p><p><strong>Conclusion: </strong>DISCERN will provide novel insight into the comparative impact of dual versus single ICI regimens in PD-L1-negative NSCLC and the potential role of ctDNA clearance as an early marker of treatment efficacy in this subset of NSCLC.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.","authors":"Noah H Richardson, Alexander S Watson, Tejas Patil, David Ross Camidge, Nasser H Hanna, Misty D Shields","doi":"10.1016/j.cllc.2025.08.015","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.015","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor Without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A Real-World Retrospective Study.","authors":"Ming Gao, Yuanliu Nie, Ting Wang, Fangfang Jing, Fan Zhang, Haitao Tao, Junxun Ma, Lijie Wang, Yi Hu","doi":"10.1016/j.cllc.2025.08.011","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.011","url":null,"abstract":"<p><strong>Objective: </strong>To explore the efficacy and safety of immune checkpoint inhibitor (ICI) without pemetrexed as first-line maintenance therapy in driver-gene negative advanced lung adenocarcinoma.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with advanced lung adenocarcinoma who were treated with pemetrexed and platinum combined with ICI as first-line therapy at PLA General Hospital from January 2019 to December 2023. Clinical data of the patients were collected and followed up. SPSS, GraphPad Prism and R were used to analyze the clinical characteristics and survival of the patients.</p><p><strong>Results: </strong>A total of 138 patients were included in this study, with a median follow-up time of 38.4 months. The median progression-free survival (PFS) of ICI maintenance group and pemetrexed plus ICI (P + ICI) maintenance group were 16.1 months (95%CI 13.9-18.2) and 11.5 months (95%CI 10.0-13.0). No statistically difference was observed between the 2 groups (P = .19). The median overall survival (OS) was 51.1 months (95% CI 32.5-69.6) for the ICI group and 43.6 months (30.4-56.8) for the P + ICI group, with no statistically difference (P = .55). The objective response rate (ORR) was 52.2% (95%CI 40.4-64.0) in the ICI group and 65.2% (95%CI 54.0-76.4) in the P + ICI group. Treatment-related adverse events (TRAEs) occurred in 91.3% and 92.8% of patients, respectively, while grade ≥ 3 events occurred in 27.5% and 30.4%. No grade 5 adverse reactions occurred.</p><p><strong>Conclusion: </strong>The maintenance treatment of ICI without pemetrexed showed good therapeutic efficacy and manageable adverse events, which can be an option as the first-line maintenance therapy for patients with driver-gene negative advanced lung adenocarcinoma.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).","authors":"Daisuke Morinaga, Megumi Furuta, Satoshi Morita, Eisaku Miyauchi, Kunihiko Kobayashi, Makoto Maemondo, Hajime Asahina","doi":"10.1016/j.cllc.2025.08.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.012","url":null,"abstract":"<p><strong>Background: </strong>In treatment-naïve advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, approximately 10% to 15% correspond to uncommon mutations. For patients with EGFR uncommon mutations, monotherapy with either a second-generation EGFR tyrosine kinase inhibitor (TKI), afatinib, or a third-generation EGFR-TKI, osimertinib, is recommended as the initial therapy. However, needs remain unmet for patients with central nervous system (CNS) metastases and those who do not respond adequately to single-agent TKI therapy for EGFR uncommon mutations. The recently published FLAURA2 trial showed that osimertinib in combination with platinum-pemetrexed significantly prolonged progression-free survival (PFS) and provided high disease control compared with osimertinib monotherapy for common mutations. Therefore, we planned this phase II study to evaluate the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations.</p><p><strong>Patients and methods: </strong>Forty patients will be enrolled in the study. The primary endpoint is the objective response rate, and the secondary endpoints include safety, PFS and overall survival in overall patients, patients with and without CNS lesions at baseline and according to mutation subtype.</p><p><strong>Conclusions: </strong>In this study, we will explore the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations. Our findings may provide treatment options for patients with EGFR uncommon mutations, especially those with CNS metastases or those requiring more intensive treatment.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaplastic Lymphoma Kinase Rearrangement and Tumor Spread Through Air Spaces Is Associated with Worse Clinical Outcomes for Resected Stage IA Lung Adenocarcinoma.","authors":"Jinghan Shi, Kuan Xu, Xufeng Liu, Minjun Shi, Chunyu Ji, Bo Ye","doi":"10.1016/j.cllc.2025.08.016","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.016","url":null,"abstract":"<p><strong>Purpose: </strong>Lung adenocarcinoma (LUAD) with anaplastic lymphoma kinase (ALK) rearrangements could be targeted with tyrosine kinase inhibitors (TKIs) to improve patient survival. However, the prognostic impacts of ALK rearrangements in resected early-stage LUAD still require clarification. This study evaluated potential clinical characteristics for ALK positivity in stage IA LUAD and identified post-resection prognostic implications.</p><p><strong>Methods: </strong>A total of 1212 non-mucinous stage IA LUAD patients who underwent curative resection were included in this retrospective analysis, and divided, based on the Ventana assay, into ALK-positive and negative groups. Uni- and multivariate logistic regression analyses investigated relationships between ALK rearrangements and clinical characteristics, while log-rank tests, Kaplan-Meier curves, and multivariate Cox regression analysis identified recurrence-free (RFS) and overall (OS) survival differences between different groups. Cumulative incidence of recurrence curves for different post-surgical groups was also calculated, and Gray's test assessed their differences. Potential confounder impacts were minimized by 1:2 greedy propensity score matching.</p><p><strong>Results: </strong>Out of 1212 cases of stage IA LUAD, 82 (6.8%) were ALK-positive. ALK-positivity was most strongly associated with tumor spread through air spaces (STAS) and International Association for the Study of Lung Cancer grade 3. STAS-positivity was also associated with worse RFS and OS. ALK- and STAS-positive patients, compared to ALK-negative, had significantly worse RFS and higher likelihood for distant metastases.</p><p><strong>Conclusions: </strong>ALK rearrangement-positivity in resected stage IA LUAD correlated with more aggressive histological features. STAS- and ALK-positive patients had worse survival and higher metastatic likelihood, compared to ALK-negative. Therefore, targeting STAS- and ALK-positive LUAD with TKIs may improve post-treatment survival rates and reduce metastatic spread.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Provider Bias in Decision Making About Treatment of Early-stage Lung Cancer With Stereotactic Body Radiation Therapy or Sub-lobar Resection.","authors":"Jeremy Mudd, Hamna Zafar, Grace Mhango, Christopher G Slatore, Raja Flores, Scott Swanson, Kenneth Rosenzweig, Jeffrey A Kern, Juan P Wisnivesky","doi":"10.1016/j.cllc.2025.08.010","DOIUrl":"10.1016/j.cllc.2025.08.010","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12498473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.","authors":"Antoine Bronstein, Hubert Curcio, Isabelle Monnet, Charles Ricordel, Laurence Bigay-Game, Margaux Geier, Chantal Decroisette, Catherine Daniel, Florian Guisier, Aurélie Swalduz, Anne Claire Toffart, Hélène Doubre, Jean Michel Peloni, Dominique Arpin, Hugues Morel, Remi Veillon, Benedicte Clarisse, Christos Chouaïd, Laurent Greillier, Olivier Bylicki","doi":"10.1016/j.cllc.2025.08.009","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.009","url":null,"abstract":"<p><strong>Background: </strong>For metastatic non-small-cell lung cancer (mNSCLC) patients with oncogenic driver progression after tyrosine kinase inhibitors (TKIs), obtaining a new mutational profile is recommended to assess the mechanism of resistance. The feasibility of that recommendation and its clinical impact remain poorly studied.</p><p><strong>Methods: </strong>mNSCLC patients with EGFR mutation and ALK or ROS translocation progressing on optimal TKI therapy were screened for inclusion in an immunochemotherapy trial not requiring a new molecular profile determination. This analysis evaluated the rebiopsy rate and its clinical impact.</p><p><strong>Results: </strong>Among 148 patients, 79 (53.4%) analyzable re-biopsies showed 72/132 (54.6%) with EGFR mutations, 7/13 (53.8%) had ALK translocations and no (0/5) ROS translocations. Seventy-nine re-biopsies were tissue (37, 46.8%), liquid (26, 32.9%) or both samples (16, 20.3%). For patients harboring EGFR mutations, the rebiopsy was not contributive for 12/72 (16.7%), the initial mutation was not found for 9/72 (12.5%) and only the unchanged initial profile was detected for 22/72 (30.6%); new information was provided for 29/72 (40.3%). Among patients with ALK-translocated mNSCLCs, re-biopsies enabled identification of resistance mechanisms for 20%. Overall survival did not differ between patients with rebiopsy and those without.</p><p><strong>Conclusions: </strong>In this population of patients with oncogenic driver progression under optimal targeted TKIs and in sufficiently good general condition to be included in an immunochemotherapy trial, only half were re-biopsied. Rebiopsy does not seem to improve the outcomes of these patients.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Changing Landscape of Lung Cancer Resection Outcomes Over the Past two Decades.","authors":"Charles-Antoine Guay, Alexandre Suhani, Laurie Perreault, Vicky Mai, Anne-Sophie Laliberté, Catherine Labbé, Steeve Provencher","doi":"10.1016/j.cllc.2025.08.006","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.08.006","url":null,"abstract":"<p><strong>Introduction: </strong>Recent advances in cancer management may have transformed the overall prognosis of patients undergoing lung cancer resection. This study aimed to assess the changes in the long-term survival of patients undergoing surgery for lung cancer over the last 2 decades and to identify the risk factors modulating the postoperative prognosis.</p><p><strong>Methods: </strong>This single-center retrospective study included nonsmall cell lung cancer patients who underwent lung resection between 2008 and 2020. Exclusion criteria included prior lung cancer or resection, diagnosis of lung metastases, small cell lung cancers, carcinoid tumors, or benign tumors. Multivariate models analyzed determinants of short- and long-term outcomes over time.</p><p><strong>Results: </strong>Among 2898 lung resections performed, 768 deaths (26.5%) occurred, including 25 (0.9%) in the 30-day postoperative period. Postoperative complications were observed in 1063 cases (36.7%), with 535 (18.5%) being respiratory-related. No significant improvement was observed in 30-day postoperative complications or deaths over time. Conversely, the adjusted hazard ratio (HR) for mortality was 0.72 (95% CI, 0.57-0.92) and 0.59 (95% CI, 0.45-0.78) for the in 2012-2015 and 2016-2020 periods compared to 2008-2011. In multivariate analyses, increasing age, current smoking at the time of surgery, pneumonectomy, advanced cancer stage and lower socioeconomic status were associated with worse outcomes.</p><p><strong>Conclusions: </strong>Over the past 2 decades, long-term survival after lung cancer resection has significantly improved, despite stable rates of early postoperative complications. Efforts to develop curative treatments for advanced stages remain crucial while public health initiatives must address socioeconomic disparities to further improve lung cancer outcomes.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}